CI Global Health Sciences Corporate Class

Series A USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date July 1996
CAD Total net assets ($CAD)
As at 2026-06-30
$254.3 million
NAVPS
As at 2026-07-10
$39.8832
MER (%)
As at 2026-03-31
2.34
Management fee (%) 1.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.7240

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

A ISC 301
DSC SO* 401
LL SO 1401
F 324
P 90324
*No new purchases directly into switch only funds.

Performance2 As at 2026-06-30

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
0.06% 5.22% 9.98% 0.06% 14.85% 1.40% -2.21% 2.61% 7.21%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.7240
2021-03-26 0.2492
2020-12-18 0.3973
2020-09-25 0.3778
2020-06-26 0.2765
Payable date Total
2020-03-20 0.6464
2019-12-13 0.4049
2019-09-27 0.4529
2019-06-21 0.4275
2019-03-22 0.6736

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series A USD
 
Portfolio allocations4 As at 2026-06-30
Asset allocation (%)
  • US Equity 83.45
  • International Equity 11.36
  • Cash and Equivalents 2.96
  • Canadian Equity 2.25
  • Other -0.02
Sector allocation (%)
  • Healthcare 92.77
  • Cash and Cash Equivalent 2.96
  • Other 2.23
  • Exchange Traded Fund 2.04
Geographic allocation(%)
  • United States 86.01
  • United Kingdom 6.67
  • Netherlands 2.39
  • Switzerland 2.32
  • Other 2.23
  • Canada 0.37
  • Denmark 0.01
Top holdings6
Sector (%)
1. Eli Lilly and Co Drugs 9.74%
2. DexCom Inc Healthcare Equipment 8.37%
3. IQVIA Holdings Inc Drugs 8.36%
4. Thermo Fisher Scientific Inc Healthcare Equipment 8.10%
5. UnitedHealth Group Inc Healthcare Services 6.71%
6. AstraZeneca PLC Drugs 6.67%
7. Johnson & Johnson Drugs 6.49%
8. Stryker Corp Healthcare Equipment 6.00%
9. Merck & Co Inc Drugs 5.97%
10. Intuitive Surgical Inc Healthcare Equipment 4.03%
11. Vertex Pharmaceuticals Inc Drugs 3.44%
12. AbbVie Inc Drugs 3.32%
13. Danaher Corp Healthcare Equipment 2.95%
14. CVS Health Corp Healthcare Services 2.90%
15. Gilead Sciences Inc Drugs 2.83%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.